From:  Real-life effectiveness of mepolizumab on remission and chronic rhinosinusitis with nasal polyps in severe eosinophilic asthma

 Changes in groups’ parameters by nasal comorbidities of patients with SEA after biological treatment.

GroupGroup 1 (n = 57) SEA with NPs and CRSGroup 2 (n = 21) SEA with CRS but no NPsGroup 3 (n = 21) SEA only (without CRS or NP)
ParametersBefore treatment4 week16 weekMonth 12pBefore treatment4 week16 weekMonth 12pBefore treatment4 week16 weekMonth 12p
FEV1 (% predicted)68 (48.5–83.5)/82 (40–110)87 (41–113)< 0.00160.5 (53–74)/69 (48–88)72 (27–102)0.08774 (51–82.7)/78 (46–100)76.5 (37–95)0.355
FVC78 (63.5–90.7)/89 (47–118)96 (49–118)< 0.00175.5 (60–80)/78 (37–92)77 (41–107)0.12980 (54–89)/82 (51–105)82 (42–98)0.876
FEV1/FVC85 (78–92)/91 (58–110)92 (73–113)0.00884 (74–92)/84 (69–108)88 (62–108)0.19691.5 (82–96)/94 (71–112)95.5 (58–108)0.41
FEV1 (lt)2.22 (1.7–2.7)//2.34 (0.82–4.10)< 0.0011.71 (1.3–2.2)//1.92 (1.5–2.3)0.0361.82 (1–2.1)//1.94 (1.3–2.4)0.034
Eo (count)1,000 (650–1,465)80 (35–190)80 (30–150)100 (65–200)< 0.001640 (570–1,030)70 (60–100)95 (57–137)80 (60–175)< 0.001440 (315–840)40 (35–80)40 (30–100)65 (40–152)< 0.001
Eo (%)10.3 (7.1–15.8)1 (0.4–1.9)0.8 (0.5–1.6)1.25 (0.7–2.2)< 0.0018.2 (6.2–11.3)1 (0.7–1.2)1.2 (0.6–1.9)1.2 (0.9–2.2)< 0.0014.6 (3.1–9.9)0.55 (0.4–1.2)0.6 (0.3–1.1)0.8 (0.5–1.8)< 0.001
Number of emergency service visits4 (2–6)//0 (0–2)< 0.0013 (2.5–4)//0 (0–2)< 0.0012 (2–4)//1 (0–2)0.001
OCS use (mg)16 (8–26)0 (0–8)/0 (0–4)< 0.0018 (8–16)0 (0–4)/0 (0–4)0.0028 (8–19)0 (0–4)/0 (0–4)0.135
Frequency of attacks4 (2–6)//1 (0–1.5)< 0.0013 (3–5)//1 (0–2)< 0.0013 (2–4)//1 (1–1.2)< 0.001
SNOT-2266 (38–96)//45 (10–90)< 0.00134 (12–53)//14 (4–33)< 0.001/////
NPS5 (6–3)//2 (4–2)< 0.001//////////
LMS22 (6–24)//15 (2–24)< 0.00113 (0–22)//7 (0–10)< 0.001/////
Return to article view

SEA: severe eosinophilic asthma; CRS: chronic rhinosinusitis; FEV1: forced expiratory volume in 1 second; FEV1 (%predicted): percent predicted FEV1; FVC: forced vital capacity; OCS: oral corticosteroid; Eo: eosinophil; NPS: nasal polyp score; LMS: Lund-Mackay CT score; SNOT-22: Sino-Nasal Outcome Test-22. /: indicates data not collected or unavailable for this timepoint. The p-value indicates the comparison between the baseline and Year 1 group; the bolded p-values indicate statistically significant results (p < 0.05).